Literature DB >> 7461013

Haemodynamic effects of a single intravenous dose of lorcainide in patients with heart disease.

T Meinertz, F Kersting, W Kasper, H Just, H Bechtold, E Jähnchen.   

Abstract

The cardiovascular effects of a single i.v. dose (2 mg/kg over 5 min) of lorcainide were studied in 14 patients with heart disease. In the haemodynamic part of the study (6 patients), the aortic and pulmonary systolic, diastolic and mean pressures, left ventricular systolic and end-diastolic pressures, cardiac output and the rate of rise of left ventricular pressure were measured before and for 30 min after administration of the drug. Lorcainide produced a slight and short-lasting decrease in the aortic and pulmonary systolic pressures, and all other pressure values remained unchanged. The cardiac output and systemic vascular resistance were not altered by lorcainide. It consistently depressed the rate of rise of left ventricular pressure (maximum mean decrease 19%). In the angiographic part of the study (8 patients), the ejection fraction and the mean velocity of circumferential fiber shortening were measured before and 5 min after lorcainide. In all but one patient, lorcainide decreased the ejection fraction (mean decrease 11.6%), and the mean velocity of circumferential fiber shortening was uniformly diminished by lorcainide (mean decrease 29.7%). Thus, lorcainide moderately impaired myocardial performance in patients with normal and reduced left ventricular function without producing hypotensive side effects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7461013     DOI: 10.1007/bf00874656

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Lorcainide. I. Saturable presystemic elimination.

Authors:  E Jähnchen; H Bechtold; W Kasper; F Kersting; H Just; J Heykants; T Meinertz
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

2.  Lorcainide. II. Plasma concentration-effect relationship.

Authors:  T Meinertz; W Kasper; F Kersting; H Just; H Bechtold; E Jähnchen
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

3.  Electrophysiological actions of lorcainide in patients with cardiac disease.

Authors:  W Kasper; T Meinertz; F Kersting; H Löllgen; K Lang; H Just
Journal:  J Cardiovasc Pharmacol       Date:  1979 May-Jun       Impact factor: 3.105

4.  Disposition and antiarrhythmic effect of lorcainide.

Authors:  U Klotz; P Müller-Seydlitz; P Heimburg
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-04

5.  Initial clinical experience of lorcainide (Ro 13-1042), a new antiarrhythmic agent.

Authors:  G Cocco; C Strozzi
Journal:  Eur J Clin Pharmacol       Date:  1978-11-16       Impact factor: 2.953

6.  Clinical experience with lorcainide (R 15 889), a new anti-arrhythmic drug.

Authors:  H Kesteloot; R Stroobandt
Journal:  Arch Int Pharmacodyn Ther       Date:  1977-12

7.  Antiarrhythmic, electrophysiologic and hemodynamic effects of lorcainide.

Authors:  E Carmeliet; P A Janssen; R Marsboom; J M Van Nueten; R Xhonneux
Journal:  Arch Int Pharmacodyn Ther       Date:  1978-01
  7 in total
  2 in total

1.  Lorcainide treatment of Wolff-Parkinson-White syndrome in children and adolescents.

Authors:  M Samánek; V Hrobonová; H Bartáková
Journal:  Pediatr Cardiol       Date:  1987       Impact factor: 1.655

Review 2.  Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  C e Eiriksson; R N Brogden
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.